|
1
|
You JM: Peripheral T-cell Lymphoma, Not
Otherwise Specified. Medeiros LJ, Miranda RN, Wang SA, Vega F,
Muzzafar T, Yin CC, Bueso-Ramos CE and Lin P: Diagnostic pathology
lymph nodes and spleen with extranodal lymphomas. Lippincott
Williams & Wilkins; Baltimore, MD: pp. 1006–1027. 2011
|
|
2
|
Dotlic S, Perry AM, Petrusevska G, Fetica
B, Diebold J, MacLennan KA, Müller-Hermelink HK, Nathwani BN,
Boilesen E, Bast M, et al: Classification of non-Hodgkin lymphoma
in South-eastern Europe: Review of 632 cases from the international
non-Hodgkin lymphoma classification project. Br J Haematol.
171:366–372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Park S and Ko YH: Peripheral T cell
lymphoma in Asia. Int J Hematol. 99:227–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pileri SA, Weisenburger DD, Sng I,
Nakamura S, Muller-Hermelink HK, Chan WC and Jaffe ES: Peripheral
T-Cell Lymphoma, NOS. Swerdlow EH, Harris NL, Jaffe ES, Pileri SA,
Stein H and Thiele J: WHO classification of tumours of
haematopoietic and lymphoid tissues. IARC; Lyon: pp. 403–407.
2017
|
|
5
|
Zheng Z, Tian R and Wang P: Roles of KAI1
and nm23 in lymphangiogenesis and lymph metastasis of laryngeal
squamous cell carcinoma. World J Surg Oncol. 15:2112017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Durán E, Cárdenas JM, Reina MÁ and Arriazu
R: Loss of Nm23 is associated with a more favorable tumor
microenvironment in patients with breast cancer. Histol
Histopathol. 30:345–352. 2015.PubMed/NCBI
|
|
7
|
Khera L, Paul C and Kaul R: Hepatitis C
Virus E1 protein promotes cell migration and invasion by modulating
cellular metastasis suppressor Nm23-H1. Virology. 506:110–120.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Radović S, Dorić M, Hukić A, Babić M,
Kuskunović S and Spahović N: Immunohistochemical expression and
significance of NM23 suppressor protein in primary gastric
adenocarcinoma. Bosn J Basic Med Sci. 13:72–77. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niitsu N, Nakamine H and Okamoto M:
Expression of nm23-H1 is associated with poor prognosis in
peripheral T-cell lymphoma, not otherwise specified. Clin Cancer
Res. 17:2893–2899. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niitsu N, Okabe-Kado J, Kasukabe T,
Yamamoto-Yamaguchi Y, Umeda M and Honma Y: Prognostic implications
of the differentiation inhibitory factor nm23-H1 protein in the
plasma of aggressive non-Hodgkin's lymphoma. Blood. 94:3541–3550.
1999.PubMed/NCBI
|
|
11
|
Niitsu N, Nakamine H, Okamoto M, Akamatsu
H, Higashihara M, Honma Y, Okabe-Kado J and Hirano M: Clinical
significance of intracytoplasmic nm23-H1 expression in diffuse
large B-cell lymphoma. Clin Cancer Res. 10:2482–2490. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou Z, Liu S, Zhang M, Zhou R, Liu J,
Chang Y and Zhao Q: overexpression of topoisomerase 2-alpha confers
a poor prognosis in pancreatic adenocarcinoma identified by
co-expression analysis. Dig Dis Sci. 62:2790–2800. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen D, Maruschke M, Hakenberg O,
Zimmermann W, Stief CG and Buchner A: TOP2A, HELLS, ATAD2, and TET3
are novel prognostic markers in renal cell carcinoma. Urology.
102:265.e1–e7. 2017. View Article : Google Scholar
|
|
14
|
Ito F, Furukawa N and Nakai T: Evaluation
of TOP2A as a predictive marker for endometrial cancer with
Taxane-containing adjuvant chemotherapy. Int J Gynecol Cancer.
26:325–330. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El Rebey HS, Aiad HA, Abulkheir IL, Asaad
NY, El-Wahed MM, Abulkasem FM and Mahmoud SF: The predictive and
prognostic role of topoisomerase IIα and tissue inhibitor of
metalloproteinases 1 expression in locally advanced breast
carcinoma of egyptian patients treated with anthracycline-based
neoadjuvant chemotherapy. Appl Immunohistochem Mol Morphol.
24:167–178. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brizova H, Kalinova M, Krskova L, Mrhalova
M and Kodet R: A novel quantitative PCR of proliferation markers
(Ki-67, topoisomerase IIalpha and TPX2): An immunohistochemical
correlation, testing, and optimizing for mantle cell lymphoma.
Virchows Arch. 456:671–679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heo MH, Park HY, Ko YH, Kim WS and Kim SJ:
IRF4/MUM1 expression is associated with poor survival outcomes in
patients with peripheral T-cell lymphoma. J Cancer. 8:1018–1024.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y, Nakayama M, Pitulescu ME, Schmidt
TS, Bochenek ML, Sakakibara A, Adams S, Davy A, Deutsch U, Lüthi U,
et al: Ephrin-B2 controls VEGF-induced angiogenesis and
lymphangiogenesis. Nature. 465:483–486. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Medinger M, Fischer N and Tzankov A:
Vascular endothelial growth factor-related pathways in
hemato-lymphoid malignancies. J Oncol 2010. 7297252010.
|
|
21
|
Koh YW, Park C, Yoon DH, Suh C and Huh J:
Prognostic significance of COX-2 expression and correlation with
Bcl-2 and VEGF expression, microvessel density and clinical
variables in classical Hodgkin lymphoma. Am J Surg Pathol.
37:1242–1251. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yang J, Li W, He X, Zhang G, Yue L and
Chai Y: VEGF overexpression is a valuable prognostic factor for
non-Hodgkin's lymphoma evidence from a systemic meta-analysis. Dis
Markers 2015. 7867902015.
|
|
23
|
Carbone PP, Kaplan HS, Musshoff K,
Smithers DW and Tubiana M: Report of the committee on Hodgkin's
disease staging classification. Cancer Res. 31:1860–1861.
1971.PubMed/NCBI
|
|
24
|
International Non-Hodgkin's Lymphoma
Prognostic Factors Project: A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee WJ, Kim YJ, Lee YJ, Won CH, Chang SE,
Choi JH and Lee MW: Vascular endothelial growth factor protein
expression is associated with a poor prognosis in patients with
cutaneous extranodal natural killer/T-cell lymphoma. Br J Dermatol.
178:e11–e12. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen JG, Chen HZ, Zhu J, Yang YL, Zhang
YH, Huang PX, Chen YS, Zhu CY, Yang LP, Shen K, et al: Cancer
survival in patients from a hospital-based cancer registry, China.
J Cancer. 9:851–860. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krzanowski M, Drelicharz L, Belowski A,
Partyka L, Sumek-Brandys B, Ramakrishnan PK and Nizankowski R:
Costs of Real-life endovascular treatment of critical limb
ischemia: Report from Poland-A European union country with a
low-budget health care system. Ann Vasc Surg. 31:111–123. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Piccaluga PP, Agostinelli C, Gazzola A,
Mannu C, Bacci F, Sabattini E and Pileri SA: Prognostic markers in
peripheral T-cell lymphoma. Curr Hematol Malig Rep. 5:222–228.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Suzuki T, Kawamoto K, Tamura S, Uemura S,
Kaihatsu A, Nemoto H, Kobayashi H, Ushiki T, Fuse K, Shibazaki Y,
et al: Peripheral T-cell lymphoma, not otherwise specified: A
retrospective single-center analysis. Rinsho Ketsueki. 58:905–911.
2017.(In Japanese). PubMed/NCBI
|
|
30
|
Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh
SJ, Jang JH, Kim K, Jung CW, Ahn YC, et al: Clinical features and
prognostic factors of patients with ‘peripheral T cell lymphoma,
unspecified’. Ann Hematol. 88:111–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gallamini A, Stelitano C, Calvi R, Bellei
M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E,
Iannitto E, et al: Peripheral T-cell lymphoma unspecified (PTCL-U):
A new prognostic model from a retrospective multicentric clinical
study. Blood. 103:2474–2479. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang QP, Zhang WY, Yu JB, Zhao S, Xu H,
Wang WY, Bi CF, Zuo Z, Wang XQ, Huang J, et al: Subtype
distribution of lymphomas in Southwest China: Analysis of 6,382
cases using WHO classification in a single institution. Diagn
Pathol. 6:772011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vose J, Armitage J and Weisenburger D;
International T-Cell Lymphoma Project, : International peripheral
T-cell and natural killer/T-cell lymphoma study: Pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Federico M, Bellei M, Marcheselli L,
Schwartz M, Manni M, Tarantino V, Pileri S, Ko YH, Cabrera ME,
Horwitz S, et al: Peripheral T cell lymphoma, not otherwise
specified (PTCL-NOS). A new prognostic model developed by the
International T cell Project Network. Br J Haematol. 181:760–769.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chihara D, Fanale MA, Miranda RN, Noorani
M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE,
Samaniego F, et al: The survival outcome of patients with
relapsed/refractory peripheral T-cell lymphoma-not otherwise
specified and angioimmunoblastic T-cell lymphoma. Br J Haematol.
176:750–758. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mak V, Hamm J, Chhanabhai M, Shenkier T,
Klasa R, Sehn LH, Villa D, Gascoyne RD, Connors JM and Savage KJ:
Survival of patients with peripheral T-cell lymphoma after first
relapse or progression: Spectrum of disease and rare long-term
survivors. J Clin Oncol. 31:1970–1976. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Weisenburger DD, Savage KJ, Harris NL,
Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura
S, Nathwani B, et al: Peripheral T-cell lymphoma, not otherwise
specified: A report of 340 cases from the International Peripheral
T-cell Lymphoma Project. Blood. 117:3402–3408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu P, Yu D, Wang L, Shen Y, Shen Z and
Zhao W: Analysis of prognostic factors and comparison of prognostic
scores in peripheral T cell lymphoma, not otherwise specified: A
single-institution study of 105 Chinese patients. Ann Hematol.
94:239–247. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Savage KJ, Harris NL, Vose JM, Ullrich F,
Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne
RD, et al: ALK-anaplastic large-cell lymphoma is clinically and
immunophenotypically different from both ALK+ ALCL and peripheral
T-cell lymphoma, not otherwise specified: Report from the
International Peripheral T-Cell Lymphoma Project. Blood.
111:5496–5504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marioni G, Cappellesso R, Ottaviano G,
Fasanaro E, Marchese-Ragona R, Favaretto N, Giacomelli L, Guzzardo
V, Martini A, Fassina A and Blandamura S: Nuclear nonmetastatic
protein 23-H1 expression and epithelial-mesenchymal transition in
laryngeal carcinoma: A pilot investigation. Head Neck.
40:2020–2028. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fu JW and Chu XQ: Correlation between
non-metastatic protein 23 expression and clinicopathological
features of colorectal cancer in Asians. Genet Mol Res.
14:15597–15608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yuan L, Chen L, Qian K, Qian G, Wu CL,
Wang X and Xiao Y: Co-expression network analysis identified six
hub genes in association with progression and prognosis in human
clear cell renal cell carcinoma (ccRCC). Genom Data. 14:132–140.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Piao J, Sun J, Yang Y, Jin T, Chen L and
Lin Z: Target gene screening and evaluation of prognostic values in
non-small cell lung cancers by bioinformatics analysis. Gene.
647:306–311. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li K, Sun H, Lu Z, Xin J, Zhang L, Guo Y
and Guo Q: Value of [18F]FDG PET radiomic features and
VEGF expression in predicting pelvic lymphatic metastasis and their
potential relationship in early-stage cervical squamous cell
carcinoma. Eur J Radiol. 106:160–166. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han W, Zhang C, Cao FY, Cao F, Jiang L and
Ding HZ: Prognostic and clinicopathological value of NM23
expression in patients with breast cancer: A systematic review and
meta-analysis. Curr Probl Cancer. 41:80–93. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Niitsu N, Nakamine H, Okamoto M, Akamatsu
H, Honma Y, Higashihara M, Okabe-Kado J and Hirano M; Adult
Lymphoma Treatment Study Group ALTSG, : Expression of nm23-H1 is
associated with poor prognosis in peripheral T-cell lymphoma. Br J
Haematol. 123:621–630. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cuadros M, Dave SS, Jaffe ES, Honrado E,
Milne R, Alves J, Rodríguez J, Zajac M, Benitez J, Staudt LM and
Martinez-Delgado B: Identification of a proliferation signature
related to survival in nodal peripheral T-cell lymphomas. J Clin
Oncol. 25:3321–3329. 2007. View Article : Google Scholar : PubMed/NCBI
|
